Moshe Mittelman

Tel Aviv University — Israel

Medicine · Health Sciences

40h-index6.6kcitations360works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(129), Erythropoietin and Anemia Treatment(65), Myeloproliferative Neoplasms: Diagnosis and Treatment(44), Multiple Myeloma Research and Treatments(40), Hemoglobinopathies and Related Disorders(38)

Publications357 total

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood
Blood·2025Open Access
Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination
Blood·2025Open Access
ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states
Blood·2025Open Access
Estimating the Causal Effect of Realistic Treatment Strategies Using Longitudinal Observational Data
Medical Decision Making·2025
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT
Leukemia Research·2025
OUTCOME RESEARCH (INCLUDING QUALITY OF LIFE) AND HEALTH ECONOMICS - PATIENT-REPORTED OUTCOMES & QUALITY OF LIFE
Leukemia Research·2025
TREATMENT - CURRENT TREATMENT OPTIONS - HIGHER RISK MDS
Leukemia Research·2025
COLLABORATIVE DEBATE SESSION: THERAPEUTIC AGENTS IN MYELODYSPLASTIC SYNDROMES – TOO FEW AND NOT EFFECTIVE ENOUGH: WE CAN DO BETTER
Leukemia Research·2025
RAPID FIRE SESSION 02
Leukemia Research·2025Open Access
WORKSHOP 02 (CONTINUES): IMPROVING TREATMENT OF MDS: FROM SUPPORTIVE CARE AND EARLY INTERVENTIONS TOWARDS TARGETED THERAPY
Leukemia Research·2025
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT
Leukemia Research·2025Open Access
Next‐generation morphology, a novel multilayer morphometric digital analysis, reveals both the basic topology and new trends of myelodysplasia of peripheral blood specimens
British Journal of Haematology·2025Open Access
POSTER: MDS-249 Outcomes With Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MDS-330 Outcomes of Imetelstat Therapy in Patients With Ring Sideroblast-Negative (RS-) Lower-Risk Myelodysplastic Syndromes (LR-MDS) From the Pooled IMerge Study Populations
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-249: OutcomesWith Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs)
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-330: Outcomes of Imetelstat Therapy in Patients With Ring Sideroblast-Negative (RS-) Lower-Risk Myelodysplastic Syndromes (LR-MDS) From the Pooled IMerge Study Populations
Clinical Lymphoma Myeloma & Leukemia·2025
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery
Blood·2025· 4 citedOpen Access
Humanized mouse models in MDS
Cell Death and Disease·2025· 1 citedOpen Access
Neutropenia (even mild) and anemia are poor prognostic factors in myelodysplastic syndromes
Frontiers in Medicine·2025· 1 citedOpen Access
MDS DIAGNOSIS? STILL BY BONE MARROW EXAMINATION?
Hematology Transfusion and Cell Therapy·2025Open Access
page 1 of 18Next →

Frequent Co-authors

Guillermo Sanz(11), Pierre Fenaux(11), Drorit Neumann(10), Eva Hellström‐Lindberg(9), David Bowen(8), Uwe Platzbecker(7), Howard S. Oster(7), Luca Malcovati(6), Jaroslav Čermák(6), Reinhard Stauder(6), Argiris Symeonidis(6), Dominik Selleslag(5), Théo de Witte(5), Aristoteles Giagounidis(5), Agnès Guerci‐Bresler(5), António Almeida(5), Max Gassmann(5), Aliza Zeidman(5), Amos Cohen(5), Consuelo del Cañizo(4)